Literature DB >> 18951437

Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.

David E Goldgar1, Douglas F Easton, Graham B Byrnes, Amanda B Spurdle, Edwin S Iversen, Marc S Greenblatt.   

Abstract

Genetic testing often results in the finding of a variant whose clinical significance is unknown. A number of different approaches have been employed in the attempt to classify such variants. For some variants, case-control, segregation, family history, or other statistical studies can provide strong evidence of direct association with cancer risk. For most variants, other evidence is available that relates to properties of the protein or gene sequence. In this work we propose a Bayesian method for assessing the likelihood that a variant is pathogenic. We discuss the assessment of prior probability, and how to combine the various sources of data into a statistically valid integrated assessment with a posterior probability of pathogenicity. In particular, we propose the use of a two-component mixture model to integrate these various sources of data and to estimate the parameters related to sensitivity and specificity of specific kinds of evidence. Further, we discuss some of the issues involved in this process and the assumptions that underpin many of the methods used in the evaluation process. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18951437      PMCID: PMC2936773          DOI: 10.1002/humu.20897

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  36 in total

1.  A full-likelihood method for the evaluation of causality of sequence variants from family data.

Authors:  Deborah Thompson; Douglas F Easton; David E Goldgar
Journal:  Am J Hum Genet       Date:  2003-07-29       Impact factor: 11.025

2.  A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.

Authors:  D G R Evans; D M Eccles; N Rahman; K Young; M Bulman; E Amir; A Shenton; A Howell; F Lalloo
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

3.  Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.

Authors:  Thaddeus Judkins; Brant C Hendrickson; Amie M Deffenbaugh; Kristilyn Eliason; Benoît Leclair; Michael J Norton; Brian E Ward; Dmitri Pruss; Thomas Scholl
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

4.  Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.

Authors:  Georgia Chenevix-Trench; Sue Healey; Sunil Lakhani; Paul Waring; Margaret Cummings; Ross Brinkworth; Amie M Deffenbaugh; Lynn Anne Burbidge; Dmitry Pruss; Thad Judkins; Tom Scholl; Anna Bekessy; Anna Marsh; Paul Lovelock; Ming Wong; Andrea Tesoriero; Helene Renard; Melissa Southey; John L Hopper; Koulis Yannoukakos; Melissa Brown; Douglas Easton; Sean V Tavtigian; David Goldgar; Amanda B Spurdle
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

5.  Classification of Missense Mutations of Disease Genes.

Authors:  Xi Zhou; Edwin S Iversen; Giovanni Parmigiani
Journal:  J Am Stat Assoc       Date:  2005       Impact factor: 5.033

6.  Missense mutations in disease genes: a Bayesian approach to evaluate causality.

Authors:  G M Petersen; G Parmigiani; D Thomas
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

7.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR).

Authors:  Elizabeth C Chao; Jonathan L Velasquez; Mavee S L Witherspoon; Laura S Rozek; David Peel; Pauline Ng; Stephen B Gruber; Patrice Watson; Gad Rennert; Hoda Anton-Culver; Henry Lynch; Steven M Lipkin
Journal:  Hum Mutat       Date:  2008-06       Impact factor: 4.878

Review 9.  Functional analysis helps to clarify the clinical importance of unclassified variants in DNA mismatch repair genes.

Authors:  Jianghua Ou; Renée C Niessen; Anne Lützen; Rolf H Sijmons; Jan H Kleibeuker; Niels de Wind; Lene Juel Rasmussen; Robert M W Hofstra
Journal:  Hum Mutat       Date:  2007-11       Impact factor: 4.878

10.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Authors:  Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

View more
  88 in total

1.  Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting.

Authors:  David K Crockett; Perry G Ridge; Andrew R Wilson; Elaine Lyon; Marc S Williams; Scott P Narus; Julio C Facelli; Joyce A Mitchell
Journal:  Genome Med       Date:  2012-05-28       Impact factor: 11.117

2.  Inactivation of DNA mismatch repair by variants of uncertain significance in the PMS2 gene.

Authors:  Mark Drost; Hester Koppejan; Niels de Wind
Journal:  Hum Mutat       Date:  2013-09-11       Impact factor: 4.878

Review 3.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

4.  In silico analysis of missense substitutions using sequence-alignment based methods.

Authors:  Sean V Tavtigian; Marc S Greenblatt; Fabienne Lesueur; Graham B Byrnes
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

5.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

6.  Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group.

Authors:  Sean V Tavtigian; Marc S Greenblatt; David E Goldgar; Paolo Boffetta
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

7.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  Assessment of functional effects of unclassified genetic variants.

Authors:  Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications.

Authors:  Sean V Tavtigian; Graham B Byrnes; David E Goldgar; Alun Thomas
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

10.  Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes.

Authors:  Marc S Greenblatt; Lawrence C Brody; William D Foulkes; Maurizio Genuardi; Robert M W Hofstra; Magali Olivier; Sharon E Plon; Rolf H Sijmons; Olga Sinilnikova; Amanda B Spurdle
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.